Holdsworth House Medical Practice

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Hidradenitis suppurativa4 trials
• HIV2 trials
• Atopic dermatitis (eczema)1 trial
• Osteoarthritis1 trial

Phase

• Phase 23 trials
• Phase 2/32 trials
• Phase 31 trial

Status

• Completed4 trials
• Active, not recruiting2 trials
• Not yet recruiting1 trial
• Terminated1 trial

Lead sponsor

• Boehringer Ingelheim3 trials
• Eli Lilly and Company2 trials
• Kirby Institute2 trials
• Bioventus LLC1 trial

Running trials

• Not yet recruiting

  Swabs in Screening for HPV (SWISH)

  NCT07790601· Kirby Institute· Source

  Contact: Dr Mark Bloch, MBBS

• Active, not recruiting

  Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis

  NCT05100225· Phase 2· Bioventus LLC· Source

• Active, not recruiting

  Age-related Clonal Haematopoiesis in an HIV Evaluation Cohort (ARCHIVE)

  NCT04641013· Kirby Institute· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• HIV1 recruiting

Closed trials

• Terminated

  A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab

  NCT06241573· Phase 2/3· Boehringer Ingelheim· Source

• Completed

  A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT06046729· Phase 2· Eli Lilly and Company· Source

• Completed

  Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

  NCT05819398· Phase 2/3· Boehringer Ingelheim· Source

• Completed

  A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial

  NCT04876391· Phase 2· Boehringer Ingelheim· Source

• Completed

  Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

  NCT04392154· Phase 3· Eli Lilly and Company· Source